US FDA seeks input on nanotechnology guidelines
This article was originally published in Scrip
Executive Summary
The US FDAwill gather public comments and data at a September 8th meeting to aid the development of guidelines for nanotechnology products. Last year an agency task force report recommended development of various guidance documents on the use of nanoscale materials (Scrip Online, July 26th, 2007). These included guidelines for sponsors on identifying the particle size for drugs and biologicals, and for submitting information on how nanoscale materials affect the manufacturing process. The meeting's primary purpose is to determine what factors the FDA should consider in providing guidance on the information and data needed to demonstrate safety and effectiveness of products containing nanoscale materials, and the circumstances under which a product's regulatory status might change owing to the presence or use of nanoscale materials.
You may also be interested in...
Biosimilars: US FDA Considering ‘Guardrails’ To Prevent Misinformation
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.
Lynparza, Keytruda Supplemental Indications Face US FDA Panel Review
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
Antibiotics: Leveraging Off-Label Efficacy Data Needed To Drive Appropriate Use, Reimbursement
Clinicians and sponsors want the US FDA to open up antibacterial labeling to include more data on efficacy against resistant pathogens and in other body sites, but regulatory restrictions may require a workaround in the form of rapid, peer-to-peer communications about the data on new products.
Need a specific report? 1000+ reports available
Buy Reports